276 related articles for article (PubMed ID: 18413831)
1. Prediction of broad spectrum resistance of tumors towards anticancer drugs.
Efferth T; Konkimalla VB; Wang YF; Sauerbrey A; Meinhardt S; Zintl F; Mattern J; Volm M
Clin Cancer Res; 2008 Apr; 14(8):2405-12. PubMed ID: 18413831
[TBL] [Abstract][Full Text] [Related]
2. Voreloxin, formerly SNS-595, has potent activity against a broad panel of cancer cell lines and in vivo tumor models.
Hoch U; Lynch J; Sato Y; Kashimoto S; Kajikawa F; Furutani Y; Silverman JA
Cancer Chemother Pharmacol; 2009 Jun; 64(1):53-65. PubMed ID: 18931998
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of anticancer effects of newly synthesized dihydropyridine derivatives in comparison to verapamil and doxorubicin on T47D parental and resistant cell lines in vitro.
Bazargan L; Fouladdel S; Shafiee A; Amini M; Ghaffari SM; Azizi E
Cell Biol Toxicol; 2008 Apr; 24(2):165-74. PubMed ID: 17805981
[TBL] [Abstract][Full Text] [Related]
4. Microarray-based expression of DNA repair genes does not correlate with growth inhibition of cancer cells by natural products derived from traditional Chinese medicine.
Konkimalla VS; Wang G; Kaina B; Efferth T
Cancer Genomics Proteomics; 2008; 5(2):79-84. PubMed ID: 18460736
[TBL] [Abstract][Full Text] [Related]
5. Factors determining sensitivity or resistance of tumor cell lines towards artesunate.
Sertel S; Eichhorn T; Sieber S; Sauer A; Weiss J; Plinkert PK; Efferth T
Chem Biol Interact; 2010 Apr; 185(1):42-52. PubMed ID: 20144594
[TBL] [Abstract][Full Text] [Related]
6. Establishment of cross-resistance profiles for new agents.
Schabel FM; Skipper HE; Trader MW; Laster WR; Griswold DP; Corbett TH
Cancer Treat Rep; 1983 Oct; 67(10):905-22. PubMed ID: 6354439
[TBL] [Abstract][Full Text] [Related]
7. Simultaneous targeting of MCL1 and ABCB1 as a novel strategy to overcome drug resistance in human leukaemia.
Ji M; Li J; Yu H; Ma D; Ye J; Sun X; Ji C
Br J Haematol; 2009 Jun; 145(5):648-56. PubMed ID: 19344413
[TBL] [Abstract][Full Text] [Related]
8. Chemosensitization of solid tumors by modulation of resistance mechanisms.
Cree IA; Knight L; Di Nicolantonio F; Sharma S; Gulliford T
Curr Opin Investig Drugs; 2002 Apr; 3(4):634-40. PubMed ID: 12090736
[TBL] [Abstract][Full Text] [Related]
9. The lignan, (-)-sesamin reveals cytotoxicity toward cancer cells: pharmacogenomic determination of genes associated with sensitivity or resistance.
Saeed M; Khalid H; Sugimoto Y; Efferth T
Phytomedicine; 2014 Apr; 21(5):689-96. PubMed ID: 24556122
[TBL] [Abstract][Full Text] [Related]
10. Predicting cancer drug response by proteomic profiling.
Ma Y; Ding Z; Qian Y; Shi X; Castranova V; Harner EJ; Guo L
Clin Cancer Res; 2006 Aug; 12(15):4583-9. PubMed ID: 16899605
[TBL] [Abstract][Full Text] [Related]
11. P-glycoprotein and its inhibition in tumors by phytochemicals derived from Chinese herbs.
Eichhorn T; Efferth T
J Ethnopharmacol; 2012 Jun; 141(2):557-70. PubMed ID: 21963565
[TBL] [Abstract][Full Text] [Related]
12. Use of tritiated nucleotide incorporation for prediction of sensitivity of tumors to cytostatic agents.
Volm M
Behring Inst Mitt; 1984 May; (74):273-84. PubMed ID: 6383325
[TBL] [Abstract][Full Text] [Related]
13. Reversal of multidrug resistance by synthetic and natural compounds in drug-resistant MCF-7 cell lines.
Kars MD; Işeri OD; Gunduz U; Molnar J
Chemotherapy; 2008; 54(3):194-200. PubMed ID: 18560226
[TBL] [Abstract][Full Text] [Related]
14. Overcoming resistance to conventional drugs in Ewing sarcoma and identification of molecular predictors of outcome.
Scotlandi K; Remondini D; Castellani G; Manara MC; Nardi F; Cantiani L; Francesconi M; Mercuri M; Caccuri AM; Serra M; Knuutila S; Picci P
J Clin Oncol; 2009 May; 27(13):2209-16. PubMed ID: 19307502
[TBL] [Abstract][Full Text] [Related]
15. Evidence for multidrug-resistant cells in human tumor cell populations.
Shoemaker RH; Curt GA; Carney DN
Cancer Treat Rep; 1983 Oct; 67(10):883-8. PubMed ID: 6313186
[TBL] [Abstract][Full Text] [Related]
16. Reversal effect of isotetrandrine, an isoquinoline alkaloid extracted from Caulis Mahoniae, on P-glycoprotein-mediated doxorubicin-resistance in human breast cancer (MCF-7/DOX) cells.
Wang TX; Yang XH
Yao Xue Xue Bao; 2008 May; 43(5):461-6. PubMed ID: 18717331
[TBL] [Abstract][Full Text] [Related]
17. Drug resistance mechanisms in cancer cells: a proteomics perspective.
Verrills NM; Kavallaris M
Curr Opin Mol Ther; 2003 Jun; 5(3):258-65. PubMed ID: 12870435
[TBL] [Abstract][Full Text] [Related]
18. Systematic analysis of the antiproliferative effects of novel and standard anticancer agents in rhabdoid tumor cell lines.
Lünenbürger H; Lanvers-Kaminsky C; Lechtape B; Frühwald MC
Anticancer Drugs; 2010 Jun; 21(5):514-22. PubMed ID: 20147838
[TBL] [Abstract][Full Text] [Related]
19. Resistance to chemotherapy in cancer: a complex and integrated cellular response.
Mellor HR; Callaghan R
Pharmacology; 2008; 81(4):275-300. PubMed ID: 18259091
[TBL] [Abstract][Full Text] [Related]
20. REIC/Dkk-3 overexpression downregulates P-glycoprotein in multidrug-resistant MCF7/ADR cells and induces apoptosis in breast cancer.
Kawasaki K; Watanabe M; Sakaguchi M; Ogasawara Y; Ochiai K; Nasu Y; Doihara H; Kashiwakura Y; Huh NH; Kumon H; Date H
Cancer Gene Ther; 2009 Jan; 16(1):65-72. PubMed ID: 18654608
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
